Cell and Gene Therapy
The fields of cell and gene therapy have seen a period of accelerated development in recent years, driven in part by parallel advances in related disciplines, particularly gene editing. J A Kemp has developed a substantial practice in these important technology areas. Our work in these fields is considerable and covers constructs, regulatory mechanisms, vectors, formulations and delivery systems for gene therapy applications, as well as cell lines and expression systems for vector manufacture. We have worked extensively on cases involving stem cells, including induced pluripotent stem cells, as well as engineered cells, reagents and methods for therapeutic use, including adoptive cell transfer techniques such as CAR T-cell therapy.
We have significant experience in drafting and prosecuting patent applications in the cell and gene therapy spaces, as well as providing freedom-to-operate advice and representation before the Opposition Divisions and Boards of Appeal at the European Patent Office (EPO). We have been involved in some high profile cases in these fields, such as representing Wisconsin Alumni Research Foundation before the Enlarged Board of Appeal in case G2/06 involving the patentability of human embryonic stem cells.
Several members of our team hold first degrees and/or PhDs in relevant technology fields and we ensure that we keep up to date with latest developments. Our expertise in these disciplines is bolstered by the strength and depth in our related practices including Gene Editing and Engineering, Immunology and Immunotherapy and RNA/Oligonucleotide technology.